Pulmonary administration of erythropoietin
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 11, 1994
Grant Date -
N/A
app pub date -
Feb 4, 1993
filing date -
Feb 4, 1993
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Erythropoietin (EPO) can be delivered systemically in therapeutically or prophylactically effective amounts by pulmonary administration using a variety of pulmonary delivery devices, including nebulizers, metered dose inhalers and powder inhalers. Aerosol administration of EPO in accordance with this invention results in significant elevation of red blood cell levels. EPO can be administered in this manner to medically treat or prevent anemia, as well as to treat or prevent other maladies related to erythropoiesis.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully